FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Musso Alan A					BE	2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [ BLCM ]								(Chec	k all applica Director	Reporting Person(s) to Issuer ble)  10% Owner give title Other (specify		ner	
(Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800					3. Date of Earliest Transaction (Month/Day/Year) 12/18/2014								Λ	X Officer (give title Officer (specify below)  CFO and Treasurer					
(Street) HOUST(	ON T	X	77030 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi Line) X	Form fil	ual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Ta	ble I - Non	-Deriv	ative	e Se	curities	s Ac	quired,	Dis	posed o	of, or Be	nefici	ally	Owned				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,		Date,	Transaction Disposed Code (Instr.			ies Acquire Of (D) (Ins		and 5) Securitie Beneficia Owned F		s Fo ally (D following (I)		: Direct I r Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	Amount (A) or (D)		e		orted isaction(s) tr. 3 and 4)			(Instr. 4)		
Common Stock 12/18/				/2014	014 A 117,647		7 <sup>(1)</sup> A	\$0	0.00	117,647			D						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative   Conversion   Date   Execution Date,   Tecurity   or Exercise   (Month/Day/Year)   if any   C		Co	ransaction Second (Instr. ) Ac or of		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			3. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Co	ode \	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amount (Instr. 4)						
Employee Stock Option (right to buy)	\$19	12/18/2014		I	A		117,647		(2)		12/03/2024	Common Stock	117,6	47	\$0.00	117,64	17	D	

## **Explanation of Responses:**

- 1. Restricted Stock Award granted under the Issuer's 2014 Equity Incentive Plan vests as follows: 25% shall vest annually upon the first anniversary of the vesting commencement date of November 24, 2014 for the first two years with the remainder vesting in equal semi-annual installments every six months for the remaining two years.
- 2. 25% of the shares subject to the stock option vest and become exercisable on November 24, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.

## Remarks:

/s/ Alan A. Musso

12/22/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.